{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:49:06Z","timestamp":1771656546270,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Regorafenib demonstrated encouraging results in recurrent glioblastoma patients. Some studies showed that changes in circulating thyroid hormones (fT3, fT4, fT3\/fT4 ratio) can be considered as prognostic factors in patients with various types of tumors. We designed this study to investigate the relationship between baseline thyroid variables and outcome in IDH-wild type GBM patients who were treated with regorafenib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicenter retrospective study included recurrent <jats:italic>IDH<\/jats:italic>-wild-type glioblastoma patients treated with regorafenib. Only patients with baseline thyroid function values (TSH, fT3, fT4, fT3\/fT4 ratio) available were evaluated. RANO criteria were used to analyze neuroradiological response. Survival curves were estimated using the Kaplan\u2013Meier method. The relationships between baseline thyroid variables (TSH, fT3, fT4, fT3\/fT4) and survival (PFS, OS) were investigated with Cox regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From November 2015 to April 2022, 134 recurrent IDH-wildtype GBM patients were treated with regorafenib and 128 of these had information on baseline thyroid function value. Median follow-up was 8\u00a0months (IQR 4.7\u201314.0). Objective Response Rate was 9% and Disease Control Rate was 40.9%. Median PFS was 2.7\u00a0months (95%CI 2.2\u20133.6) and median OS was 10.0\u00a0months (95%CI 7.0\u201313.0). Lower baseline TSH value in the blood was correlated with a higher rate of disease progression to regorafenib (p\u2009=\u20090.04). Multivariable analyses suggested a non-linear relationship between PFS (p\u2009=\u20090.01) and OS (p\u2009=\u20090.03) with baseline fT3\/fT4 ratio.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In recurrent wild-type IDH glioblastoma patients, baseline fT3\/fT4 ratio showed a non-linear relationship with survival, with different impacts across the spectrum of fT3\/fT4 ratio. Moreover, baseline TSH may be a predictor of regorafenib activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-023-04356-w","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T18:02:05Z","timestamp":1685642525000},"page":"377-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study"],"prefix":"10.1007","volume":"163","author":[{"given":"Mario","family":"Caccese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Chioffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Della Puppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cavallin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Pittaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"4356_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C et al (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol 24:v1\u2013v95. https:\/\/doi.org\/10.1093\/neuonc\/noac202","journal-title":"Neuro Oncol"},{"key":"4356_CR2","doi-asserted-by":"crossref","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996.","DOI":"10.1056\/NEJMoa043330"},{"key":"4356_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245\u2013255. https:\/\/doi.org\/10.1002\/ijc.25864","journal-title":"Int J Cancer"},{"key":"4356_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295\u2013302. https:\/\/doi.org\/10.1016\/S0140-6736(12)61857-1","journal-title":"Lancet"},{"key":"4356_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"key":"4356_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"4356_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110\u2013119","journal-title":"Lancet Oncol"},{"key":"4356_CR8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1210\/jc.2017-02149","volume":"103","author":"G Pasqualetti","year":"2018","unstructured":"Pasqualetti G, Calsolaro V, Bernardini S et al (2018) Degree of peripheral thyroxin deiodination, frailty, and long-term survival in hospitalized older patients. J Clin Endocrinol Metab 103:1867\u20131876. https:\/\/doi.org\/10.1210\/jc.2017-02149","journal-title":"J Clin Endocrinol Metab"},{"key":"4356_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/clc.22689","volume":"40","author":"V Lamprou","year":"2017","unstructured":"Lamprou V, Varvarousis D, Polytarchou K et al (2017) The role of thyroid hormones in acute coronary syndromes: prognostic value of alterations in thyroid hormones. Clin Cardiol 40:528\u2013533. https:\/\/doi.org\/10.1002\/clc.22689","journal-title":"Clin Cardiol"},{"key":"4356_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/gerona\/glt012","volume":"68","author":"W De Alfieri","year":"2013","unstructured":"De Alfieri W, Nistico F, Borgogni T et al (2013) Thyroid hormones as predictors of short- and long-term mortality in very old hospitalized patients. J Gerontol A Biol Sci Med Sci 68:1122\u20131128. https:\/\/doi.org\/10.1093\/gerona\/glt012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"4356_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5527\/wjn.v4.i3.415","volume":"4","author":"S Fragidis","year":"2015","unstructured":"Fragidis S, Sombolos K, Thodis E et al (2015) Low T3 syndrome and long-term mortality in chronic hemodialysis patients. World J Nephrol 4:415\u2013422. https:\/\/doi.org\/10.5527\/wjn.v4.i3.415","journal-title":"World J Nephrol"},{"key":"4356_CR12","doi-asserted-by":"publisher","first-page":"e0181878","DOI":"10.1371\/journal.pone.0181878","volume":"12","author":"M Pinter","year":"2017","unstructured":"Pinter M, Haupt L, Hucke F et al (2017) The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS ONE 12:e0181878. https:\/\/doi.org\/10.1371\/journal.pone.0181878","journal-title":"PLoS ONE"},{"key":"4356_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12672-014-0183-0","volume":"5","author":"ZA Yasar","year":"2014","unstructured":"Yasar ZA, Kirakli C, Yilmaz U et al (2014) Can non-thyroid illness syndrome predict mortality in lung cancer patients? A prospective cohort study. HORM CANC 5:240\u2013246. https:\/\/doi.org\/10.1007\/s12672-014-0183-0","journal-title":"HORM CANC"},{"key":"4356_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bjh.14528","volume":"177","author":"R Gao","year":"2017","unstructured":"Gao R, Liang J-H, Wang L et al (2017) Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma. Br J Haematol 177:95\u2013105. https:\/\/doi.org\/10.1111\/bjh.14528","journal-title":"Br J Haematol"},{"key":"4356_CR15","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1016\/j.clcc.2018.05.013","volume":"17","author":"M Schirripa","year":"2018","unstructured":"Schirripa M, Pasqualetti G, Giampieri R et al (2018) Prognostic value of thyroid hormone ratios in patients with advanced metastatic colorectal cancer treated with regorafenib: the TOREADOR study. Clin Colorectal Cancer 17:e601\u2013e615. https:\/\/doi.org\/10.1016\/j.clcc.2018.05.013","journal-title":"Clin Colorectal Cancer"},{"key":"4356_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2020.04.023","volume":"133","author":"G Pasqualetti","year":"2020","unstructured":"Pasqualetti G, Schirripa M, Dochy E et al (2020) Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: results from the phase III randomised CORRECT trial. Eur J Cancer 133:66\u201373. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.023","journal-title":"Eur J Cancer"},{"key":"4356_CR17","doi-asserted-by":"publisher","unstructured":"Maruzzo M, Verzoni E, Vitale MG et al (2021) Prognostic value of thyroid hormone ratio in patients with advanced metastatic renal cell carcinoma: results from the threefour study (Meet-URO 14). Front Oncol 11:787835. https:\/\/doi.org\/10.3389\/fonc.2021.787835","DOI":"10.3389\/fonc.2021.787835"},{"key":"4356_CR18","unstructured":"R Core Team (2022) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"4356_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JOE-09-0412","volume":"205","author":"MH Warner","year":"2010","unstructured":"Warner MH, Beckett GJ (2010) Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 205:1\u201313. https:\/\/doi.org\/10.1677\/JOE-09-0412","journal-title":"J Endocrinol"},{"key":"4356_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/s0022-3476(05)80288-4","volume":"119","author":"AL Ogilvy-Stuart","year":"1991","unstructured":"Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR (1991) Thyroid function after treatment of brain tumors in children. J Pediatr 119:733\u2013737. https:\/\/doi.org\/10.1016\/s0022-3476(05)80288-4","journal-title":"J Pediatr"},{"key":"4356_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1210\/jc.2002-020380","volume":"88","author":"M Schmiegelow","year":"2003","unstructured":"Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK et al (2003) A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. J Clin Endocrinol Metab 88:136\u2013140. https:\/\/doi.org\/10.1210\/jc.2002-020380","journal-title":"J Clin Endocrinol Metab"},{"key":"4356_CR22","doi-asserted-by":"publisher","unstructured":"Cosnarovici MM, Piciu A, Bonci E-A, et al (2020) Post-treatment thyroid diseases in children with brain tumors: a single-center experience at \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, Cluj-Napoca. Diagnostics (Basel) 10:142. https:\/\/doi.org\/10.3390\/diagnostics10030142","DOI":"10.3390\/diagnostics10030142"},{"key":"4356_CR23","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1210\/jc.2011-0306","volume":"96","author":"NM Appelman-Dijkstra","year":"2011","unstructured":"Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM et al (2011) Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab 96:2330\u20132340. https:\/\/doi.org\/10.1210\/jc.2011-0306","journal-title":"J Clin Endocrinol Metab"},{"key":"4356_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539\u20131547. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722","journal-title":"J Clin Oncol"},{"key":"4356_CR25","doi-asserted-by":"publisher","first-page":"34678","DOI":"10.1021\/acsami.0c09973","volume":"12","author":"Y Shang","year":"2020","unstructured":"Shang Y, Kuang M, Wang Z et al (2020) An ultrashort peptide-based supramolecular hydrogel mimicking IGF-1 to alleviate glucocorticoid-induced sarcopenia. ACS Appl Mater Interfaces 12:34678\u201334688. https:\/\/doi.org\/10.1021\/acsami.0c09973","journal-title":"ACS Appl Mater Interfaces"},{"key":"4356_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jsbmb.2006.11.024","volume":"105","author":"P Kaasik","year":"2007","unstructured":"Kaasik P, Umnova M, Pehme A et al (2007) Ageing and dexamethasone associated sarcopenia: peculiarities of regeneration. J Steroid Biochem Mol Biol 105:85\u201390. https:\/\/doi.org\/10.1016\/j.jsbmb.2006.11.024","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04356-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04356-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04356-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T08:07:36Z","timestamp":1688544456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04356-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4356"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04356-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Veneto Insitute of Oncology IOV-IRCCS Ethics Committee\u00a0(EC Number: 2020\/154)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}